These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28914717)

  • 1. The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
    Mills AM; Dill EA; Moskaluk CA; Dziegielewski J; Bullock TN; Dillon PM
    Am J Surg Pathol; 2018 Feb; 42(2):183-191. PubMed ID: 28914717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
    Kir G; Olgun ZC; Soylemez T; Aydin A; Demircan B; Kaya IA; McCluggage WG
    Int J Gynecol Pathol; 2021 Nov; 40(6):575-586. PubMed ID: 33332859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
    Özcan D; Lade-Keller J; Tramm T
    Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors.
    Wen YH; Brogi E; Zeng Z; Akram M; Catalano J; Paty PB; Norton L; Shia J
    Am J Surg Pathol; 2012 Nov; 36(11):1700-8. PubMed ID: 22992699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
    Jessup CJ; Redston M; Tilton E; Reimann JD
    Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of DNA mismatch repair proteins in prostate cancer.
    Sharma M; Yang Z; Miyamoto H
    Medicine (Baltimore); 2020 May; 99(19):e20124. PubMed ID: 32384491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas.
    Sari A; Pollett A; Eiriksson LR; Lumsden-Johanson B; Van de Laar E; Kazerouni H; Salehi A; Sur M; Lytwyn A; Ferguson SE
    Am J Surg Pathol; 2019 May; 43(5):591-600. PubMed ID: 30864976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
    Hou Y; Nitta H; Parwani AV; Li Z
    Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
    Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
    Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
    Hacking S; Jin C; Komforti M; Liang S; Nasim M
    Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphological predictors for microsatellite instability in urothelial carcinoma.
    Sobrino-Reig E; Meizoso T; García J; Varillas-Delgado D; Martin YB
    Diagn Pathol; 2021 Nov; 16(1):106. PubMed ID: 34801034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas.
    Rowe M; Krishnan R; Mills A; Ring K
    Int J Gynecol Cancer; 2020 Jul; 30(7):993-999. PubMed ID: 32376735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
    Mills AM; Liou S; Ford JM; Berek JS; Pai RK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1501-9. PubMed ID: 25229768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
    Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
    Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
    Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
    Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency.
    Clay MR; Allison KH; Folkins AK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3.
    Wu S; Shi X; Wang J; Wang X; Liu Y; Luo Y; Mao F; Zeng X
    Front Immunol; 2021; 12():561793. PubMed ID: 33717059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.